<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C49C66E3-8EF1-43E8-82A1-7A8347F84C2B"><gtr:id>C49C66E3-8EF1-43E8-82A1-7A8347F84C2B</gtr:id><gtr:name>Sentinel Oncology Limited</gtr:name><gtr:address><gtr:line1>SUITE 52 23 SCIENCE PARK , MILTON ROAD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C49C66E3-8EF1-43E8-82A1-7A8347F84C2B" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>C49C66E3-8EF1-43E8-82A1-7A8347F84C2B</gtr:id><gtr:name>Sentinel Oncology Limited</gtr:name><gtr:address><gtr:line1>SUITE 52 23 SCIENCE PARK , MILTON ROAD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>228332.0</gtr:offerGrant><gtr:projectCost>380553.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=600304"><gtr:id>A77DFB7C-CA91-455F-A595-B73EA6E8A790</gtr:id><gtr:title>FXSFIX</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>EU-Funded</gtr:grantCategory><gtr:grantReference>600304</gtr:grantReference><gtr:abstractText>FXSFIX will deliver a diagnostic biomarker for use with SOL101, a clinical candidate drug for the treatment of
Fragile X Syndrome (FXS). SOL101 is a first in class drug for FXS which is an orphan disease with no current
clinically available treatments. SOL101 is an inhibitor of p70 S6 kinase 1 (S6K1), a protein recently shown to have
utility in the control of aberrant protein production which is a phenotypic hallmark of FXS and will aim to reverse the
symptoms suffered by patients.</gtr:abstractText><gtr:fund><gtr:end>2018-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2016-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>228332</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">600304</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>